Interstitial Lung Disease Research Unit Biobank

NCT05392881 | Recruiting

• 1 other identifier: STUDY00144558
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Conditions

Interstitial Lung Disease; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Hypersensitivity Pneumonitis

Keywords

Interstitial Lung Disease; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Hypersensitivity Pneumonitis

Outcome Measures

Primary Outcomes (5)

• Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.

  Enrollment to Year 10

• Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.

  Enrollment to Year 10

• Correlate biological samples with individual longitudinal clinical data.

  Enrollment to Year 10

• Provide biological samples to researchers performing studies in ILD and RLD.

  Enrollment to Year 10

• Collect historical data and imaging from deceased patients with ILD.

  Enrollment to Year 10

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with ILD, RLD and subjects at risk for ILD

You may qualify if:

• The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
• The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
• The participant is ≥ 18 years of age.
• The participant has signed an approved consent for this study (living patients only)

Sponsors & Collaborators

• University of Kansas Medical Center: lead

Study Sites (1)

The University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

RECRUITING

MeSH Terms

Conditions

Lung Diseases, Interstitial; Sarcoidosis; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Alveolitis, Extrinsic Allergic

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Respiratory Hypersensitivity; Hypersensitivity, Immediate

Study Officials

• Scott Matson, M.D.

  University of Kansas Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kimberly Donnelly, Ph.D.

CONTACT

913-588-6067; kdonnelly@kumc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Medicine

Study Record Dates

• First Submitted: May 22, 2022
• First Posted: May 26, 2022
• Study Start: August 9, 2021
• Primary Completion (Estimated): August 1, 2031
• Study Completion (Estimated): March 1, 2032
• Last Updated: September 22, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (1)